Companies: 10,795·Total market cap: $144.5T
Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLINASDAQHealthcare● Active
$19.54
+$0.02(+0.10%)
Market Cap$3.1B
P/E Ratio—
52W High$23.77
52W Low$12.58
SEC Filings

Denali Therapeutics Inc. (DNLI) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001714899 · DNLI · NASDAQ · as of Jun 8, 2026

Filing snapshot

772
Total Filings
4
Latest Form
2026-06-05
Most Recent
2017
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001714899 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001714899-26-000021
Primary Document
dnli-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001714899 · Accession 0001714899-26-000021

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-04
View
8-KCurrent Report
8-K
2026-05-22
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
3/AInitial Statement of Beneficial Ownership (Amended)
FORM 3/A
2026-04-21
View
DEFA14AProxy Statement (Additional)
DEFA14A ADDITIONAL MATERIALS
2026-04-21
View
ARSARS
ARS
2026-04-21
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-20
View
8-KCurrent Report
8-K
2026-04-03
View
8-KCurrent Report
8-K
2026-03-31
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-25
View
Showing 1–15 of 295 filingsForm 4 / 144 hidden· 772 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001714899  |  Exchange: NASDAQ · Healthcare

Denali Therapeutics Inc. (NASDAQ: DNLI) has submitted 772 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001714899, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Denali Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Denali Therapeutics Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical DNLI 10-K annual reports are available from 2017 through 2026.

Investors researching Denali Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
IBRX SEC Filings →LQDA SEC Filings →COGT SEC Filings →BEAM SEC Filings →RCUS SEC Filings →ETNB SEC Filings →GLPG SEC Filings →AGIO SEC Filings →
→ DNLI Financials→ DNLI Earnings→ DNLI Insider Trades

Frequently Asked Questions

DNLI SEC Filings · 8 questions

Denali Therapeutics Inc. (DNLI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 772 filings and access original documents at no cost. Denali Therapeutics Inc.'s CIK is 0001714899.

DNLI SEC filingsDenali Therapeutics Inc. SEC documentsfind DNLI 10-K